Flow Dysfunction of Hemodialysis Vascular Access

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

375 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The FLOW trial evaluates the follow-up of the vascular access for hemodialysis. In current clinical care, vascular access flow volume is periodically assessed to detect and treat asymptomatic stenosis. The FLOW trial will determine whether it is safe to abandon this practice of active surveillance. Vascular access stenosis will then be treated only when clinical problems of flow dysfunction occur during hemodialysis. The investigators expect that the intervention rate and medical costs will be reduced by 40% when correction of vascular access stenosis is triggered by clinically apparent access dysfunction rather than asymptomatic flow reduction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Relationship Between the Flow of Arteriovenous Fistula and Cardiac Function in Haemodialysis Patients

NCT02747966

Complication of Hemodialysis

COMPLETED

Preoperative Arteriovenous Fistula Simulation Study (ShuntSimulationStudy)

NCT02453412

Kidney Failure, Chronic Arteriovenous Fistulae

COMPLETED NA

Effect of Increased Convective Clearance by On-Line Hemodiafiltration on All Cause Mortality in Chronic Hemodialysis Patients

NCT00205556

End-stage Renal Disease Cardiovascular Disease

COMPLETED NA

Access Flow Based Intervention for Management of Arteriovenous Hemodialysis Access Dysfunction.

NCT02628119

Hemodialysis Arteriovenous Fistula Maturation Failure

UNKNOWN NA

ACCESS HD: Comparing Catheters to Fistulas in Elderly Patients Starting Hemodialysis

NCT02675569

End-stage Kidney Failure

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design: Multicenter randomized controlled trial with 375 patients. Patients will be followed up for 2 to 3 years. The trial is powered to detect a reduction in the intervention rate of 0.25 per year between study groups in a superiority analysis (this is associated with cost savings of 1 million euros per year in the Netherlands). Subgroup analyses of arteriovenous fistulas and grafts and of successful and failed interventions will be done.

On 25-02-2025, the sample size was reduced from 417 to 375 patients because updated calculations based on actual event and loss to follow-up rates in the trial population showed sufficient power to detect the prespecified clinically relevant difference.

Study population: Chronic hemodialysis patients with a functioning arteriovenous fistula or graft.

Intervention group: Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy.

Control group: Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume \<500mL/min, or when clinical signs of flow dysfunction are present.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dialysis Access Malfunction Hemodialysis Access Failure Hemodialysis Fistula Thrombosis Vascular Access Malfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double blind randomized controlled trial with hybrid parallel-crossover design

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

The software of the HD03 Hemodialysis Monitor will be adjusted to allow blinded measurements that will be sent to the trial coordinator; patients and health care providers remain unaware of treatment allocation and surveillance findings. Flow measurements will only be used to refer patients for correction of vascular access stenosis in the control group. To maintain blinding, whenever a measurement must be repeated to confirm low flow volumes, another trial participant will randomly be selected for confirmation of vascular access flow volumes after the next measurement. Patients will be censored and randomized anew following an intervention for flow dysfunction, as soon as the indicator for vascular access intervention has been resolved and vascular access function has been restored.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy.

Group Type EXPERIMENTAL